Physician profile
Ted Edwards
NPI 1932189560
$2,492.40
in general payments reported to CMS, 2019-2025
31 companies · $396 in 2025
The $396 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $240 · 2021: $143 · 2022: $228 · 2023: $410 · 2024: $615 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,421.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $296.20 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Neurocrine Biosciences, INC. | $270.54 | 2023-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $252.65 | 2020-2025 | Ultomiris |
| Eisai INC. | $223.37 | 2024-2025 | |
| Argenx US, INC. | $218.68 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Abbvie INC. | $160.63 | 2023-2025 | Botox |
| Pfizer INC. | $152.90 | 2019-2025 | |
| Boston Scientific Corporation | $131.55 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Greenwich Biosciences, INC. | $79.97 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $75.56 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $64.07 | 2022-2023 | Epidiolex |
| Amgen INC. | $60.13 | 2019-2020 | |
| Sk Life Science, INC. | $55.58 | 2022-2024 | |
| Biodelivery Sciences International, INC. | $51.57 | 2019 | |
| Ucb, INC. | $50.76 | 2019-2025 | Rystiggo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $42.46 | 2019-2020 | |
| Lundbeck LLC | $35.81 | 2022-2025 | Vyepti |
| Assertio Therapeutics, INC. | $31.59 | 2019 | |
| Impel Pharmaceuticals INC. | $27.72 | 2022 | |
| Banner Life Sciences, LLC | $26.18 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $21.42 | 2021 | |
| Grifols USA, LLC | $21.20 | 2025 | Gamunex-C |
| Scilex Pharmaceuticals INC. | $19.72 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.34 | 2025 | Relistor |
| Otsuka America Pharmaceutical, INC. | $18.16 | 2025 | Rexulti |
| Depuy Synthes Sales INC. | $16.82 | 2022 | |
| Currax Pharmaceuticals LLC | $15.03 | 2023 | Onzetra Xsail |
| Medtronic USA, INC. | $14.08 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.66 | 2021 | |
| Almatica Pharma LLC | $12.89 | 2023 | Gralise |
| Biogen, INC. | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.